Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus

The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus Opinion EDITORIAL The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus Marc G. Ghany, MD, MHSc 5-7 Chronic hepatitis C virus (HCV) infection accounts for ciency virus or hepatitis B virus. It is estimated that approxi- approximately 30% of cases of cirrhosis and one-quarter mately 25% of individuals will progress to cirrhosis or of hepatocellular carcinomas worldwide and is the decompensated liver disease over a period of 25 to 30 years. leading indication for liver Therefore, treating a patient early in the course of their dis- transplant in the adult US ease would expose them to unnecessary toxicity and compli- population. Although the in- cations from treatment with unproven benefit on outcome of Related article page 178 cidence of chronic HCV infec- their liver disease. tion is declining in the United States, the number of deaths is In this issue of JAMA Internal Medicine, Butt and projected to rise over the next decade because of complica- colleagues report rather provocative results from an analy- tions among persons infected 30 to 40 years ago. Hence, the sis of a Department of Veterans Affairs database, which sug- major reasons for treating chronic HCV infection are to miti- gests http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus

JAMA Internal Medicine , Volume 175 (2) – Feb 1, 2015

Loading next page...
 
/lp/american-medical-association/the-ongoing-debate-of-who-to-treat-for-chronic-hepatitis-c-virus-e9AMhgWjDK
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2014.4299
pmid
25486410
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus Marc G. Ghany, MD, MHSc 5-7 Chronic hepatitis C virus (HCV) infection accounts for ciency virus or hepatitis B virus. It is estimated that approxi- approximately 30% of cases of cirrhosis and one-quarter mately 25% of individuals will progress to cirrhosis or of hepatocellular carcinomas worldwide and is the decompensated liver disease over a period of 25 to 30 years. leading indication for liver Therefore, treating a patient early in the course of their dis- transplant in the adult US ease would expose them to unnecessary toxicity and compli- population. Although the in- cations from treatment with unproven benefit on outcome of Related article page 178 cidence of chronic HCV infec- their liver disease. tion is declining in the United States, the number of deaths is In this issue of JAMA Internal Medicine, Butt and projected to rise over the next decade because of complica- colleagues report rather provocative results from an analy- tions among persons infected 30 to 40 years ago. Hence, the sis of a Department of Veterans Affairs database, which sug- major reasons for treating chronic HCV infection are to miti- gests

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Feb 1, 2015

References